Podcasts

Episode 36 | Antibody Drug Conjugates (ADCs): An Emerging Treatment Platform in Lung Cancer

Thoracic Oncology Group of Australasia podcast, hosted by: A/Prof Melissa Moore, A/Prof Tom John and A/Prof Adnan Nagrial

Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs.

A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from Westmead Hospital in Sydney.

Tile for TOGA podcasts series episode on ADCs

Play Episode 36 | Antibody Drug Conjugates (ADCs): An Emerging Treatment Platform in Lung Cancer

More Podcasts

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.
Host A/Prof Rachel Roberts-Thomson leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital
In this episode, we welcome A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health.